Should You Buy I-Mab ADR (IMAB) Stock on Tuesday?

The market has been neutral on I-Mab ADR (IMAB) stock recently. IMAB gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

I-Mab ADR has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on IMAB!

See Full IMAB Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With IMAB Stock Today?

I-Mab ADR (IMAB) stock is unchanged -0.39% while the S&P 500 is lower by -1.4% as of 1:47 PM on Tuesday, Sep 26. IMAB is unmoved $0.00 from the previous closing price of $1.28 on volume of 526,351 shares. Over the past year the S&P 500 is higher by 17.01% while IMAB is lower by -72.09%. IMAB lost -$3.68 per share in the over the last 12 months.

More About I-Mab ADR

I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Click Here to get the full Stock Report for I-Mab ADR stock.